RecallRadar

FDA Drug recall D-0761-2023

buPROPrion Hydrochloride Extended-Release Tablets, USP (SR) 150 mg, 60 Tablets, Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc…

On 2023-05-31 the FDA classified a Class II recall of buPROPrion Hydrochloride Extended-Release Tablets, USP (SR) 150 mg, 60 Tablets, Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc… by Sun Pharmaceutical Industries, citing failed Dissolution Specifications; during stability testing.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0761-2023
ClassificationClass II
Statusterminated
Initiated2023-05-09
Published2023-05-31
Last updated2026-09-13 11:52 UTC
CompanySun Pharmaceutical Industries
DistributionUS

Product

buPROPrion Hydrochloride Extended-Release Tablets, USP (SR) 150 mg, 60 Tablets, Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ, Manufactured by: Sun Pharmaceutical Industries Limited, Gujrat, India, NDC 47335-737-86

Reason

Failed Dissolution Specifications; during stability testing

Identifiers

ndc47335-736-86
ndc47335-736-88
ndc47335-736-08
ndc47335-736-13
ndc47335-737-86
ndc47335-737-88
ndc47335-737-08
ndc47335-737-13
ndc47335-738-86
ndc47335-738-88
ndc47335-738-08
ndc47335-738-13
code_infoLots: HAC2240A, Exp 05/2023; HAC3162A, Exp 07/2023

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0761-2023%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.